Phase I/II Randomized Study of Combination Immunotherapy With or Without Polysaccharide Krestin (PSK®) Concurrently With a HER2 ICD Peptide-Based Vaccine in Patients With Stage IV Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Polysaccharide K (Primary) ; Cancer vaccine HER-2 neu; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 27 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 18 Jan 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.